VYNE Therapeutics Inc.
VYNE
$1.43
-$0.45-23.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.53% | 6.14% | 46.67% | -1.01% | 1,166.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.53% | 6.14% | 46.67% | -1.01% | 1,166.67% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 10.53% | 6.14% | 46.67% | -1.01% | 1,166.67% |
| SG&A Expenses | -18.40% | -2.18% | 2.11% | 16.36% | 4.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.07% | 108.13% | 1.35% | 25.18% | -13.54% |
| Operating Income | -86.91% | -109.99% | -0.76% | -25.62% | 14.43% |
| Income Before Tax | -95.22% | -100.25% | 6.41% | -11.21% | 20.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -95.29% | -100.25% | 6.41% | -11.21% | 20.73% |
| Earnings from Discontinued Operations | 77.78% | -- | 45.00% | 20.00% | 98.35% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.28% | -84.64% | 6.48% | -11.15% | 37.78% |
| EBIT | -86.91% | -109.99% | -0.76% | -25.62% | 14.43% |
| EBITDA | -87.39% | -- | -- | -- | 14.46% |
| EPS Basic | -39.29% | 85.77% | 92.81% | 91.50% | 93.92% |
| Normalized Basic EPS | -43.37% | 84.57% | 92.80% | 91.50% | 92.42% |
| EPS Diluted | -39.29% | 85.77% | 92.81% | 91.38% | 93.92% |
| Normalized Diluted EPS | -43.37% | 84.57% | 92.80% | 91.50% | 92.42% |
| Average Basic Shares Outstanding | 36.18% | 1,197.59% | 1,200.73% | 1,208.17% | 947.87% |
| Average Diluted Shares Outstanding | 36.18% | 1,197.59% | 1,200.73% | 1,208.17% | 947.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |